Michael Davidson

Stories

Europe approves obicetrapib, first CETP inhibitor to reach market after two decades of failures

As of September 2026: Leading the company through European launch and US regulatory submission

The European Commission approved two obicetrapib-based cholesterol drugs on September 21, 2026. It's the first time any CETP inhibitor has reached the market, after Pfizer, Roche, Eli Lilly and Merck spent billions on the drug class and failed.

Updated Sep 21